Positive Press Coverage Somewhat Unlikely to Impact CytomX Therapeutics (CTMX) Stock Price
News articles about CytomX Therapeutics (NASDAQ:CTMX) have been trending positive recently, according to Accern Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. CytomX Therapeutics earned a daily sentiment score of 0.26 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 47.3510776446722 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
CytomX Therapeutics stock traded up $0.01 on Friday, reaching $23.10. The company’s stock had a trading volume of 190,842 shares, compared to its average volume of 336,566. The firm has a market cap of $1.04 billion, a P/E ratio of -19.91 and a beta of 1.04. CytomX Therapeutics has a twelve month low of $15.17 and a twelve month high of $35.00.
CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). The business had revenue of $21.34 million during the quarter, compared to analyst estimates of $16.48 million. CytomX Therapeutics had a negative return on equity of 74.84% and a negative net margin of 44.46%. equities analysts forecast that CytomX Therapeutics will post -1.5 EPS for the current year.
In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 13,052 shares of the business’s stock in a transaction on Monday, July 2nd. The stock was sold at an average price of $23.42, for a total value of $305,677.84. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Debanjan Ray sold 3,000 shares of the business’s stock in a transaction on Wednesday, August 1st. The stock was sold at an average price of $26.05, for a total value of $78,150.00. Following the completion of the transaction, the chief financial officer now directly owns 8,638 shares in the company, valued at approximately $225,019.90. The disclosure for this sale can be found here. In the last three months, insiders sold 28,577 shares of company stock worth $692,875. Insiders own 8.50% of the company’s stock.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Featured Story: Short Selling Stocks, A Beginner’s Guide
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.